Action Sage Therapeutics (SAGE)

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.